Boulder, Colorado, United States
• Designed and synthesized inhibitors for eIF4E, a highly oncogenic and historically intractable target whose expression is increased, or upregulated, in a variety of human cancers • Successfully executed the challenging syntheses of several highly complex bioactive heterocycles in 15 to 20 steps • Proactively contributed in designing targets using data and structure/ligand-based drug design for optimizing potency • Improved the PK and ADME/Tox for safer and better in vivo efficacy • As a key member of the chemistry team, compiled in-house progress reports, presentations, actively participated and advised CRO for analog syntheses
• Synthesis hit to lead validation for a new scaffold in Cystic fibrosis project • Explored new methodology with parallel synthesis and high throughput chemistry to prepare libraries of compounds • Part of internal intelligence team to identify competitor molecules
Advisor: Peter G. Schultz, Arnab Chatterjee Project 1: Developed and synthesized small molecule inhibitors of fibrosis and preformed scale up chemistry in collaboration with Bristol-Myers Squibb. Project 2: Developed and synthesized (a) Non-systemic drug approach for Epithelial Sodium Channel (ENaC) inhibitors for cystic fibrosis and (b) Non-systemic drug approach for Ileal Bile Acid Transporter Inhibition (ASBT) inhibitor for Chronic Constipation, Cholestatic Pruritus, and NASH. Project 3: Developed and synthesized small molecule approach for Spinal Muscular Atrophy to enable formulations/mice efficacy studies. Project 4: Synthesized and optimized Antibody-drug conjugates (ADC) and developed cleavage linker technologies to attach drug payload to antibodies and Folate.
Advisor: Seth B. Herzon Direct Synthesis of N-Glycosides by the Reductive Glycosylation of Azides Using Protected and Native Carbohydrate Donors